Key result
Pentoxifylline reduces proteinuria by ~23% versus placebo in type 2 diabetic nephropathy.
Why the study?
Previous studies on pentoxifylline's renoprotective effects in diabetic nephropathy were limited by small sample sizes, necessitating a larger randomized trial.
Does pentoxifylline reduce proteinuria and improve glucose control in patients with type 2 diabetes and albuminuria on standard ACEI/ARB therapy?
Population
174 patients with type 2 diabetes and albuminuria on ACEI or ARB therapy
Comparison
Pentoxifylline 1200 mg daily vs placebo
Design
Prospective randomized double-blind placebo-controlled multicenter study
Follow-up
6 months
Authors
Loading...
Pentoxifylline add-on reduced residual proteinuria in type 2 diabetic nephropathy on ACEI/ARB; leaves open long-term renal and glycemic benefits.
RCT (n=174)
Double-blind
computer-generated allocation system
Yes
Does pentoxifylline reduce proteinuria and improve glucose control in patients with type 2 diabetes and albuminuria on standard ACEI/ARB therapy?
Absolute Event Rate: -23% vs -4%
p-value: p=0.012
Pentoxifylline added to standard ACEI/ARB therapy significantly reduces proteinuria and improves glycemic control in patients with type 2 diabetic nephropathy.
Han et al. (2015) conducted an RCT in Type 2 diabetes with albuminuria (n=174). Pentoxifylline vs. Placebo was evaluated on Percentage change from baseline to final on-treatment in proteinuria (p=0.012). Pentoxifylline therapy significantly reduced proteinuria by 23% from baseline compared to a 4% reduction with placebo in patients with type 2 diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: